Nachman Norwood & Parrott’s Haemonetics HAE Stock Holding History

Nachman Norwood & Parrott’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-55	Closed	-$5K	–	577
2020 Q3	$5K	Buy	+55	New	+$4.81K	﹤0.01%	953

Other funds holding HAE

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Nachman Norwood & Parrott's HAE Position: Q4 2020 in Review

Nachman Norwood & Parrott sold out of Haemonetics (HAE) in Q4 2020, closing a stake of 55 shares — an estimated $5K sold.

Nachman Norwood & Parrott first reported a position in HAE in Q3 2020 and held it in 1 quarter. The position peaked at $5K in Q3 2020. 286 funds tracked by Wall St. Rank hold HAE as of Q4 2020.

Nachman Norwood & Parrott reported no remaining Haemonetics position as of Q4 2020 after selling out during the quarter.
Nachman Norwood & Parrott sold 55 Haemonetics shares in Q4 2020, an estimated $5K.
Nachman Norwood & Parrott first reported a position in Haemonetics in Q3 2020 and held it in 1 quarter.
Nachman Norwood & Parrott's Haemonetics position peaked at $5K in Q3 2020.
286 funds tracked by Wall St. Rank held Haemonetics as of Q4 2020.

Based on Nachman Norwood & Parrott's 13F filing for Q4 2020, filed 19 Jan 2021.